Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$82.91
-0.4%
$55.70
$28.66
$91.00
$8.94B0.5964,004 shs719,013 shs
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.42
-2.1%
$1.24
$0.98
$1.60
$1.09B1.52.82 million shs1.76 million shs
Organogenesis stock logo
ORGO
Organogenesis
$2.34
-1.7%
$2.45
$2.04
$7.08
$306.24M1.32958,292 shs760,789 shs
7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
-0.41%+14.17%+45.25%+157.88%+16.38%
OPKO Health, Inc. stock logo
OPK
OPKO Health
-2.07%-1.39%+27.93%+19.33%+5.19%
Organogenesis stock logo
ORGO
Organogenesis
-1.68%-3.31%-13.33%-11.36%-28.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$82.91
-0.4%
$55.70
$28.66
$91.00
$8.94B0.5964,004 shs719,013 shs
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.42
-2.1%
$1.24
$0.98
$1.60
$1.09B1.52.82 million shs1.76 million shs
Organogenesis stock logo
ORGO
Organogenesis
$2.34
-1.7%
$2.45
$2.04
$7.08
$306.24M1.32958,292 shs760,789 shs
7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
-0.41%+14.17%+45.25%+157.88%+16.38%
OPKO Health, Inc. stock logo
OPK
OPKO Health
-2.07%-1.39%+27.93%+19.33%+5.19%
Organogenesis stock logo
ORGO
Organogenesis
-1.68%-3.31%-13.33%-11.36%-28.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
2.75
Moderate Buy$88.837.14% Upside
OPKO Health, Inc. stock logo
OPK
OPKO Health
2.17
Hold$1.559.15% Upside
Organogenesis stock logo
ORGO
Organogenesis
2.00
Hold$5.75145.73% Upside

Current Analyst Ratings Breakdown

Latest OPK, CORT, and ORGO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/2/2026
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
Boost Price TargetBuy$75.00 ➝ $95.00
5/28/2026
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
Set Price Target$135.00
5/28/2026
Organogenesis stock logo
ORGO
Organogenesis
Set Price Target$3.00
5/28/2026
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
Boost Price TargetBuy$110.00 ➝ $135.00
5/28/2026
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
Boost Price TargetBuy$75.00 ➝ $95.00
5/28/2026
Organogenesis stock logo
ORGO
Organogenesis
Initiated CoverageHold$3.00
5/18/2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
UpgradeSell (E+)Sell (D-)
5/13/2026
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
UpgradeNeutralBuy$44.00 ➝ $72.00
5/11/2026
Organogenesis stock logo
ORGO
Organogenesis
DowngradeHold (C)Sell (D)
5/8/2026
Organogenesis stock logo
ORGO
Organogenesis
DowngradeBuyNeutral
5/4/2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
DowngradeSell (D-)Sell (E+)
(Data available from 6/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$761.41M11.69$0.90 per share92.22$6.16 per share13.46
OPKO Health, Inc. stock logo
OPK
OPKO Health
$606.90M1.77N/AN/A$1.67 per share0.85
Organogenesis stock logo
ORGO
Organogenesis
$564.17M0.53$0.64 per share3.68$2.36 per share0.99
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$99.65M$0.35236.8928.59N/A6.14%7.40%5.76%7/30/2026 (Estimated)
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$225.68M-$0.27N/AN/AN/A-36.63%-16.78%-10.98%7/30/2026 (Estimated)
Organogenesis stock logo
ORGO
Organogenesis
$37.03M-$0.19N/AN/AN/A-0.84%9.63%4.76%8/6/2026 (Estimated)

Latest OPK, CORT, and ORGO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026
Organogenesis stock logo
ORGO
Organogenesis
-$0.29-$0.37-$0.08-$0.44$43.26 million$37.23 million
4/30/2026Q1 2026
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
-$0.1085-$0.30-$0.1915-$0.30$185.83 million$164.90 million
4/28/2026Q1 2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.07-$0.07N/A-$0.07$130.51 million$124.20 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
N/AN/AN/AN/AN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
N/AN/AN/AN/AN/A
Organogenesis stock logo
ORGO
Organogenesis
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
N/A
2.86
2.77
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.28
3.61
3.17
Organogenesis stock logo
ORGO
Organogenesis
0.05
3.53
3.16

Institutional Ownership

CompanyInstitutional Ownership
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
93.61%
OPKO Health, Inc. stock logo
OPK
OPKO Health
64.63%
Organogenesis stock logo
ORGO
Organogenesis
49.57%

Insider Ownership

CompanyInsider Ownership
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
20.70%
OPKO Health, Inc. stock logo
OPK
OPKO Health
49.69%
Organogenesis stock logo
ORGO
Organogenesis
33.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
300107.35 million85.13 millionOptionable
OPKO Health, Inc. stock logo
OPK
OPKO Health
1,373755.09 million379.89 millionOptionable
Organogenesis stock logo
ORGO
Organogenesis
950128.68 million86.21 millionOptionable

Recent News About These Companies

Organogenesis Earnings Call: Deep Pain, Long Road
Organogenesis Holdings, Inc. Class A
Why is Organogenesis Stock (ORGO) Up 20% Today?
Organogenesis stock surges 20% on trial results

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Corcept Therapeutics stock logo

Corcept Therapeutics NASDAQ:CORT

$82.91 -0.34 (-0.41%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$82.64 -0.27 (-0.32%)
As of 06/12/2026 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

OPKO Health stock logo

OPKO Health NASDAQ:OPK

$1.42 -0.03 (-2.07%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$1.44 +0.02 (+1.06%)
As of 06/12/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

Organogenesis stock logo

Organogenesis NASDAQ:ORGO

$2.34 -0.04 (-1.68%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$2.33 -0.01 (-0.64%)
As of 06/12/2026 06:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.